Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10/7/26 16:04 | 10/5/26 | MRNA | Health | BioPrd | Biological Products, (No Diag | Mock James M | MA | O | CFO | 6 | M.dm | 5,299 | 74.11 | 0 | 72 | 999% | 74 | D | ||||||||||||||
9/16/26 16:48 | 9/14/26 | MRNA | Health | BioPrd | Biological Products, (No Diag | Hoge Stephen | MA | O | P | 6 | M.dm | 18,185 | 51.74 | 0 | 351 | 26 | 1,718 | D | ||||||||||||||
9/16/26 16:48 | 9/14/26 | MRNA | Health | BioPrd | Biological Products, (No Diag | Hoge Stephen | MA | O | P | 6 | S.dm | -18,185 | 51.74 | 0 | -351 | 1,718 | D | |||||||||||||||
9/8/26 16:57 | 9/4/26 | MRNA | Health | BioPrd | Biological Products, (No Diag | Klinger Shannon Thyme | MA | O | GC | 4 | M.dm | 593 | 26.96 | 0 | 22 | 37 | 81 | D | ||||||||||||||
8/7/26 16:11 | 8/5/26 | MRNA | Health | BioPrd | Biological Products, (No Diag | Bancel Stephane | MA | DO | CEO | 2 | M.dm | 43,110 | 34.46 | 0 | 1,251 | 6 | 22,216 | D | ||||||||||||||
8/7/26 16:11 | 8/5/26 | MRNA | Health | BioPrd | Biological Products, (No Diag | Bancel Stephane | MA | DO | CEO | 2 | S.dm | -43,110 | 34.46 | 0 | -1,251 | 22,216 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |